2024年,阿斯利康的安达唐(达格列净片)晋升新药王,销售68亿元,同比增长30.8%。安达唐于2023年国谈成功纳入医保,2024年是纳入医保后的首年,果然销售大增,医保魔力充分显现。达格列净可用于治疗2型糖尿病及慢性肾脏病(CKD)。#01Top20变化和2023年相比,2024年,中国终端医药市场Top20品牌中,新增5个,即诺欣妥(沙库巴曲缬沙坦钠片,诺华)、阿美乐(甲磺酸阿美替尼片,豪森...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.